FemBloc
Phase 3- Indications
- Permanent birth control
Company intelligence / Profile preview
Femasys has four approved products ready for sale in the US, Europe, and Canada. Its FDA-cleared FemaSeed® Intratubal Insemination offers a cost-effective alternative to IVF. FemBloc®, its non-surgical permanent birth control solution, is in late-stage clinical development. The company also markets diagnostic tools for fallopian tube assessment and cervical cancer diagnosis. Clinical results indicate safety and effectiveness with regulatory clearances achieved in multiple regions.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Femasys Inc..